Ultragenyx price target lowered to $100 from $140 at Truist

TipRanks

Thu, May 8, 2025, 7:25 AM 1 min read

Truist lowered the firm’s price target connected Ultragenyx (RARE) to $100 from $140 and keeps a Buy standing connected the shares. The company’s Q1 results were in-line and the absorption reiterated its FY25 gross guidance, though the firm’s price target is chopped connected tampered outlook for cistron therapy programs, the expert tells investors successful a probe note.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals successful TipRanks' Smart Value Newsletter.

• Receive undervalued stocks, resilient to marketplace uncertainty, delivered consecutive to your inbox.

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected RARE:

Disclaimer & DisclosureReport an Issue

• Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Promising Pipeline and Consistent Demand

• Ultragenyx Pharmaceutical: Undervalued Stock with Promising Pipeline and Strategic Entry Point

• Investors volition beryllium rewarded for buying Ultragenyx astatine $35, says Citi

• Buy Recommendation for Ultragenyx Pharmaceutical Driven by Strong Commercial Execution and Promising Pipeline

• Ultragenyx Pharmaceutical: Promising Developments and Strategic Progress Drive Buy Rating